News >

Expert Explores Future of CDK4/6 Inhibitors in Breast Cancer

Brandon Scalea
Published: Thursday, Jan 10, 2019

Dr Matthew Goetz
Matthew Goetz, MD
FDA approvals of 3 CDK4/6 inhibitors have added important treatment options to the armamentarium for patients with hormone receptor (HR)–positive breast cancer, but the future will focus on defining mechanisms of acquired and de novo resistance to these agents, said Matthew P. Goetz, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication